Antibody response to seasonal influenza vaccination in multiple sclerosis patients receiving immunomodulatory therapy
European Journal of Neurology
Dec 08, 2017
Olberg HK, et al. - The authors performed this study to examine the influence of immunomodulatory therapies on the antibody response and seroprotection rates in multiple sclerosis (MS) patients immunized with seasonal influenza vaccine in 2012/2013 compared to healthy controls. They proposed that in cases of insufficient protection, MS patients receiving fingolimod or natalizumab ought to be considered for a second dose of the vaccine. The outcomes further showed that new immunomodulatory treatment regimens needed to be systematically assessed for their influence on influenza-specific vaccine responses.
Go to Original
Sign-up to continue reading. It is free & takes less than 2 mins
45 lakhs+ doctors trust M3 globally
Free & unlimited access to original articles and quizzes
Secure: we never sell your data
This article is only available to members. Are you a doctor? Click here to signup for free.
Try M3 India / Log In